Search results
Results from the WOW.Com Content Network
He is a graduate of Columbia University’s medical school, and obtained psychiatry residency training within the Icahn School of Medicine at Mount Sinai and child-adolescent psychiatry fellowship ...
Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. [1] He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters.
With a wide variety of treatment methods, it can take time to find the one that works best for you. ... One type of therapy that has been gaining traction in the medical community is ketamine ...
Ketamine-assisted psychotherapy (KAP) is the use of prescribed doses of ketamine as an adjunct to psychotherapy sessions. KAP shows significant potential in treating mental disorders such as treatment-resistant depression (TRD), anxiety, obsessive–compulsive disorders (OCD), post-traumatic stress disorders (PTSD), and other conditions. [1]
Prescriptions for ketamine have soared in recent years, driven by for-profit clinics and telehealth services offering the medication as a treatment for pain, depression, anxiety and other conditions.
The New York Eye and Ear Infirmary of Mount Sinai is ranked #14 in ophthalmology. [49] Mount Sinai was ranked 8th among medical schools in the U.S. receiving NIH grants in 2022, [50] and 2nd in research dollars per principal investigator among U.S. medical schools by the Association of American Medical Colleges (AAMC). [51]
Feifel, a professor emeritus of psychiatry at the University of California, San Diego’s School of Medicine, was one of the first doctors to use ketamine off-label to treat depression at the ...
[12] [15] The United States Food and Drug Administration has granted "breakthrough therapy" status, which expedites the potential approval of promising drug therapies, [note 2] to psychedelic therapies using psilocybin (for treatment-resistant depression and major depressive disorder) [6] and MDMA (for post-traumatic stress disorder).